Articles

A phase 2, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation

Medical University of South Carolina Children's Hospital/Hollings Cancer Center, Charleston, SC
Sarah Cannon Transplant and Cellular Therapy Program, Mountain View Hospital, Las Vegas, NV
University Hospital for Internal Medicine V, Hematology and Oncology, Medical University, Innsbruck
Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CISC), Universidad de Sevilla, Sevilla
Medizinische Klinik und Poliklinik 1, Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden
University of North Carolina at Chapel Hill, Chapel Hill, NC
Jazz Pharmaceuticals, Palo Alto, CA
Jazz Pharmaceuticals, Philadelphia, PA
Jazz Pharmaceuticals, Palo Alto, CA
CHU de Lille, INSERM U1286, Infinite, 59000 Lille
Haematologica Early view Dec 15, 2022 https://doi.org/10.3324/haematol.2022.281471